DYAI

Dyadic InternationalA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

$0.35-$0.04 (-9.77%)

At close · 2026-11-12

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$0.75

Analysis reference price unavailable

Analysis 2026-09-24 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.43

Analysis reference price unavailable

Analysis 2026-09-24 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$0.24

Analysis reference price unavailable

Analysis 2026-09-24 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-24

AI commentary

Coverage in the packet is concentrated around the August Q2 results. Company-reported commercialization progress is constructive, but flat quarterly revenue and going-concern doubt temper it. Reliable social, options, short-interest, employee-rating, analyst-revision, and post-release price-reaction data were unavailable; zero sentiment fields denote missing data, not neutral readings. The deterministic directional prior is neutral, and no material thesis change is established.

RankAlpha Sentiment Codex - 2026-09-24

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31eventConversion of pilot sales into repeat ordersHigh impact

Dyadic reported shipments of six recombinant protein products after quarter-end and initial pilot sales, but repeat-order economics remain unproven. Sustained purchasing through customers and distribution partners would be stronger evidence of commercialization than shipments alone [#SEC-8K-2026-08-12]. Q2 earnings exhibit.

2026-12-31catalystFinancing and runwayHigh impact

Dyadic agreed in August to sell 3.625 million shares and warrants for another 3.625 million shares, for approximately $2.9 million in expected gross proceeds. The cited filing said closing was expected, not completed. Confirmation of proceeds and the subsequent cash runway matter because management reported substantial going-concern doubt [#8-K-2026-08-14] [#SEC-10Q-2026-08-12]. Offering filing; quarterly filing.

2027-06-30catalystFunded antibody-program preclinical progressHigh impact

Dyadic said it was working toward delivering C1-produced RSV or malaria antibody material to support preclinical studies. Delivery and subsequent results could validate the platform, but no trial-readout date or clinical outcome was established [#SEC-8K-2026-08-12]. Q2 earnings exhibit.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-24 • Updated nightlySource: Internal modelMethodology